Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
» ACUS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ACUS



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT 11.10
ACUS's EV-to-EBIT is ranked higher than
84% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. ACUS: 11.10 )
ACUS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 11.1

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, AGN, FRX, MRX, ESALF » details
Acusphere Inc. was organized as a Delaware corporation on July 12, 1993. The company is a specialty pharmaceutical company, develops drugs and improved formulations of existing drugs using its proprietary microparticle technology. The company's main product, Imagify (perflubutane polymer microspheres for delivery in an injectable suspension) is a cardiovascular drug in Phase 3 clinical development for the detection of coronary artery disease. The company's technology enables it to control the size and porosity of microparticles and nanoparticles. It focuses on creating porous particles that are smaller than red blood cells. These microparticles and nanoparticles can be used to deliver gases or to deliver drugs to patients through various routes of delivery. The company has developed proprietary spray drying equipment and pore forming processes that enable it to produce these porous microparticles in a versatile manner. The company has applied this technology in its research and development efforts in the following areas: Imagify, Intravenous Delivery of Gas for Ultrasound Contrast: The company specifically designed Imagify to assess myocardial perfusion, or blood flow in the heart muscle, a sensitive marker for coronary artery disease, or CAD. Imagify is a cardiovascular drug that enables cardiac stress ultrasound to obtain information on myocardial perfusion, or blood flow in the heart muscle. The company has completed two Phase 3 pivotal clinical trials for Imagify and intends to submit an NDA seeking approval to market and sell Imagify. Hydrophobic Drug Delivery System, HDDS: The Company's HDDS technology improves the dissolution rate of a variety of hydrophobic drugs. It has completed a Phase 1 clinical trial for AI-850, which is a product candidate that, utilizing HDDS technology, is designed to improve the dissolution rate of a cancer drug. Its PDDS technology has the potential to provide sustained release drug administration in the lung and can be targeted to deliver the drug to the upper or lower region of the lungs. The company has completed a Phase 1 study for AI-128 that, utilizing PDDS technology, demonstrated sustained release of an FDA-approved asthma drug. Competition The Company's products & technology compete with Cardiolite, which is marketed by Avista Capital Partners Medical Imaging business; Myoview, which is marketed by GE Healthcare; and thallium, which is marketed by GE Healthcare, Avista Capital Partners Medical Imaging business and Tyco International.
» More Articles for ACUS

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide